Pedro Lopez Lopez
Internal Medicine · Guayama, PRNPI 1588751317
Payments from drug & device makers
Across 53 payments — averaging $27.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$427
- Johnson & Johnson$388
- E.r. Squibb & Sons, L.L.C.$137
- Pfizer$125
- Bayer Puerto Rico Inc.$109
- AstraZeneca$93
- plus $203 from 6 others
What the payments were for
- Food & beverage$1,46099%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 14 | $427 |
| Johnson & Johnson | 16 | $388 |
| E.r. Squibb & Sons, L.L.C. | 2 | $137 |
| Pfizer | 1 | $125 |
| Bayer Puerto Rico Inc. | 5 | $109 |
| AstraZeneca | 6 | $93 |
| Gilead | 1 | $57 |
| PBG Puerto Rico LLC | 3 | $47 |
| Merck | 2 | $38 |
| AbbVie | 1 | $24 |
| Morphosys, US Inc. | 1 | $22 |
| Abbott | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PREVNAR - 13$125
- JARDIANCE$125
How this compares
$1,481 in reported general payments places this provider in the 70th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 470 | $327,015 |
| XareltoRivaroxaban | 337 | $244,945 |
| FarxigaDapagliflozin Propanediol | 293 | $211,079 |
| JardianceEmpagliflozin | 179 | $159,970 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 147 | $109,020 |
| TradjentaLinagliptin | 146 | $106,493 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 139 | $94,295 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 131 | $86,663 |
| LantusInsulin Glargine,hum.Rec.Anlog | 540 | $80,406 |
| SynjardyEmpagliflozin/Metformin Hcl | 133 | $79,990 |
| GlyxambiEmpagliflozin/Linagliptin | 107 | $73,757 |
| SynthroidLevothyroxine Sodium | 828 | $62,480 |
| JanumetSitagliptin Phos/Metformin Hcl | 73 | $55,392 |
| JentaduetoLinagliptin/Metformin Hcl | 64 | $51,005 |
| Atorvastatin Calcium | 3,857 | $48,626 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Trijardy Xr, Synjardy | $427 | $749,5921,069 claims |
| PfizerEliquis | $125 | $327,015470 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $93 | $280,351466 claims |
| Johnson & JohnsonXarelto | $388 | $244,945337 claims |
| MerckJanumet, Januvia | $38 | $90,181101 claims |
| AbbVieSynthroid | $24 | $62,480828 claims |
| GileadBiktarvy | $57 | $48,34812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in Guayama
- Elizabeth BarrancoPonce$8M
- Grisell Ortiz LasantaSan Juan$5.9M
- Ruben Santiago-LugoGuaynabo$1.3M
- Nelson VallejoLas Piedras$621K
- Ricardo FernandezSan Juan$480K
- Ronald Collazo PaganManati$206K
- Evelyn Matta FontanetRio Grande$200K
- Angel VinuelaDorado$182K
- Lumen Vera ColonAibonito$179K
- Pedro del Valle de TomasSan Juan$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.